Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2023

Open Access 01-12-2023 | Mantle Cell Lymphoma | Review

Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents

Authors: Neeraj Jain, Mukesh Mamgain, Sayan Mullick Chowdhury, Udita Jindal, Isha Sharma, Lalit Sehgal, Narendranath Epperla

Published in: Journal of Hematology & Oncology | Issue 1/2023

Login to get access

Abstract

Mantle cell lymphoma is a B cell non-Hodgkin lymphoma (NHL), representing 2–6% of all NHLs and characterized by overexpression of cyclin D1. The last decade has seen the development of many novel treatment approaches in MCL, most notably the class of Bruton's tyrosine kinase inhibitors (BTKi). BTKi has shown excellent outcomes for patients with relapsed or refractory MCL and is now being studied in the first-line setting. However, patients eventually progress on BTKi due to the development of resistance. Additionally, there is an alteration in the tumor microenvironment in these patients with varying biological and therapeutic implications. Hence, it is necessary to explore novel therapeutic strategies that can be effective in those who progressed on BTKi or potentially circumvent resistance. In this review, we provide a brief overview of BTKi, then discuss the various mechanisms of BTK resistance including the role of genetic alteration, cancer stem cells, tumor microenvironment, and adaptive reprogramming bypassing the effect of BTK inhibition, and then provide a comprehensive review of current and emerging therapeutic options beyond BTKi including novel agents, CAR T cells, bispecific antibodies, and antibody–drug conjugates.
Literature
1.
Rimokh R, Berger F, Delsol G, Digonnet I, Rouault JP, Tigaud JD, et al. Detection of the chromosomal translocation t (11; 14) by polymerase chain reaction in mantle cell lymphomas. 1994.
2.
Beà S, Amador V. Role of SOX11 and genetic events cooperating with cyclin D1 in mantle cell lymphoma. Curr Oncol Rep. 2017;19:1–10.CrossRef
3.
Maddocks K. Update on mantle cell lymphoma. Blood J Am Soc Hematol. 2018;132(16):1647–56.
4.
Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, et al. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. Blood Adv. 2023;7(11):2287–96.PubMedCrossRef
5.
Epperla N, Hamadani M, Fenske TS, Costa LJ. Incidence and survival trends in mantle cell lymphoma. Br J Haematol. 2017;181(5):703–6.PubMedCrossRef
6.
Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13:1–18.CrossRef
7.
Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369(6):507–16.PubMedPubMedCentralCrossRef
8.
Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391(10121):659–67.PubMedCrossRef
9.
Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H, et al. Treatment of patients with relapsed or refractory mantle-cell lymphoma with zanubrutinib, a selective inhibitor of Bruton’s tyrosine KinaseZanubrutinib for relapsed/refractory MCL. Clin Cancer Res. 2020;26(16):4216–24.PubMedCrossRef
10.
Mato AR, Shah NN, Jurczak W, Cheah CY, Pagel JM, Woyach JA, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021;397(10277):892–901.PubMedCrossRef
11.
Martin P. Ibrutinib–a new standard treatment for relapsed mantle cell lymphoma? Lancet. 2016;387(10020):728–9.PubMedCrossRef
12.
Jain P, Kanagal-Shamanna R, Zhang S, Ahmed M, Ghorab A, Zhang L, et al. Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. Br J Haematol. 2018;183(4):578–87.PubMedCrossRef
13.
Nakhoda S, Vistarop A, Wang YL. Resistance to Bruton tyrosine kinase inhibition in chronic lymphocytic leukaemia and non-Hodgkin lymphoma. Br J Haematol. 2023;200(2):137–49.PubMedCrossRef
14.
Epperla N, Hamadani M, Cashen AF, Ahn KW, Oak E, Kanate AS, et al. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory mantle cell lymphoma—a “real world” study. Hematol Oncol. 2017;35(4):528–35.PubMedCrossRef
15.
Zhao X, Lwin T, Silva A, Shah B, Tao J, Fang B, et al. Unification of de novo and acquired ibrutinib resistance in mantle cell lymphoma. Nat Commun. 2017;8:14920.PubMedPubMedCentralCrossRef
16.
17.
Correction: Cell-cycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov. 2019;9(11):1629.
18.
Cheng S, Guo A, Lu P, Ma J, Coleman M, Wang YL. Functional characterization of BTK(C481S) mutation that confers ibrutinib resistance: exploration of alternative kinase inhibitors. Leukemia. 2015;29(4):895–900.PubMedCrossRef
19.
Eyre TA, Cheah CY, Wang ML. Therapeutic options for relapsed/refractory mantle cell lymphoma. Blood. 2022;139(5):666–77.PubMedCrossRef
20.
Smith CIE, Burger JA. Resistance mutations to BTK inhibitors originate from the NF-kappaB but not from the PI3K-RAS-MAPK arm of the B cell receptor signaling pathway. Front Immunol. 2021;12:689472.PubMedPubMedCentralCrossRef
21.
George B, Chowdhury SM, Hart A, Sircar A, Singh SK, Nath UK, et al. Ibrutinib resistance mechanisms and treatment strategies for B-cell lymphomas. Cancers (Basel). 2020;12(5):1328.PubMedCrossRef
22.
Gomez EB, Ebata K, Randeria HS, Rosendahl MS, Cedervall EP, Morales TH, et al. Preclinical characterization of pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor. Blood. 2023;142(1):62–72.PubMedPubMedCentral
23.
Cohen JB, Shah NN, Alencar AJ, Gerson JN, Patel MR, Fakhri B, et al. MCL-133 pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study. Clin Lymphoma Myeloma Leuk. 2022;22(Suppl 2):S394–5.CrossRef
24.
Wang ML, Shah NN, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, et al. Efficacy of pirtobrutinib in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: additional patients and extended follow-up from the phase 1/2 BRUIN study. Blood. 2022;140(Supplement 1):9368–72.CrossRef
25.
Ito R, Eyre TA, Shah NN, Gouill SL, Dreyling M, Vandenberghe E, et al. MCL-135 BRUIN MCL-321, a phase 3 open-label, randomized study of pirtobrutinib versus investigator choice of BTK Inhibitor in patients with previously treated, btk inhibitor naive mantle cell lymphoma (trial in progress). Clin Lymphoma Myeloma Leuk. 2022;22(Suppl 2):S395–6.CrossRef
26.
Byrd JC, Smith S, Wagner-Johnston N, Sharman J, Chen AI, Advani R, et al. First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL. Oncotarget. 2018;9(16):13023–35.PubMedPubMedCentralCrossRef
27.
28.
29.
Dobrovolsky D, Wang ES, Morrow S, Leahy C, Faust T, Nowak RP, et al. Bruton tyrosine kinase degradation as a therapeutic strategy for cancer. Blood. 2019;133(9):952–61.PubMedPubMedCentralCrossRef
30.
Buhimschi AD, Armstrong HA, Toure M, Jaime-Figueroa S, Chen TL, Lehman AM, et al. Targeting the C481S ibrutinib-resistance mutation in Bruton’s tyrosine kinase using PROTAC-mediated degradation. Biochemistry. 2018;57(26):3564–75.PubMedCrossRef
31.
Jaime-Figueroa S, Buhimschi AD, Toure M, Hines J, Crews CM. Design, synthesis and biological evaluation of Proteolysis Targeting Chimeras (PROTACs) as a BTK degraders with improved pharmacokinetic properties. Bioorg Med Chem Lett. 2020;30(3):126877.PubMedCrossRef
32.
Sun Y, Ding N, Song Y, Yang Z, Liu W, Zhu J, et al. Degradation of Bruton’s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas. Leukemia. 2019;33(8):2105–10.PubMedCrossRef
33.
Lim YS, Yoo SM, Patil V, Kim HW, Kim HH, Suh B, et al. Orally bioavailable BTK PROTAC active against wild-type and C481 mutant BTKs in human lymphoma CDX mouse models. Blood Adv. 2023;7(1):92–105.PubMedCrossRef
34.
Zhang L, Yao Y, Zhang S, Liu Y, Guo H, Ahmed M, et al. Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Sci Transl Med. 2019;11:491.CrossRef
35.
Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, et al. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20(1):87–92.PubMedCrossRef
36.
Lenz G, Balasubramanian S, Goldberg J, Rizo A, Schaffer M, Phelps C, et al. Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial. J Clin Oncol. 2016;34(15_suppl):7570.CrossRef
37.
Vidal-Crespo A, Rodriguez V, Matas-Cespedes A, Lee E, Rivas-Delgado A, Gine E, et al. The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-kappaB mutational status. Haematologica. 2017;102(11):e447–51.PubMedPubMedCentralCrossRef
38.
Wu C, de Miranda NF, Chen L, Wasik AM, Mansouri L, Jurczak W, et al. Genetic heterogeneity in primary and relapsed mantle cell lymphomas: Impact of recurrent CARD11 mutations. Oncotarget. 2016;7(25):38180–90.PubMedPubMedCentralCrossRef
39.
Agarwal R, Chan YC, Tam CS, Hunter T, Vassiliadis D, Teh CE, et al. Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma. Nat Med. 2019;25(1):119–29.PubMedCrossRef
40.
Bea S, Valdes-Mas R, Navarro A, Salaverria I, Martin-Garcia D, Jares P, et al. Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci USA. 2013;110(45):18250–5.PubMedPubMedCentralCrossRef
41.
Mohanty A, Sandoval N, Das M, Pillai R, Chen L, Chen RW, et al. CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma. Oncotarget. 2016;7(45):73558–72.PubMedPubMedCentralCrossRef
42.
Naeem A, Utro F, Wang Q, Cha J, Vihinen M, Martindale S, et al. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 2023;7(9):1929–43.PubMedCrossRef
43.
Che Y, Liu Y, Yao Y, Hill HA, Li Y, Cai Q, et al. Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutations. Blood Cancer J. 2023;13(1):27.PubMedPubMedCentralCrossRef
44.
Wang H, Zhang W, Yang J, Zhou K. The resistance mechanisms and treatment strategies of BTK inhibitors in B-cell lymphoma. Hematol Oncol. 2021;39(5):605–15.PubMedPubMedCentralCrossRef
45.
Chen Z, Ayala P, Wang M, Fayad L, Katz RL, Romaguera J, et al. Prospective isolation of clonogenic mantle cell lymphoma-initiating cells. Stem Cell Res. 2010;5(3):212–25.PubMedPubMedCentralCrossRef
46.
Mathur R, Sehgal L, Braun FK, Berkova Z, Romaguerra J, Wang M, et al. Targeting Wnt pathway in mantle cell lymphoma-initiating cells. J Hematol Oncol. 2015;8:63.PubMedPubMedCentralCrossRef
47.
Song S, Li Y, Zhang K, Zhang X, Huang Y, Xu M, et al. Cancer Stem cells of diffuse large B cell lymphoma are not enriched in the CD45(+)CD19(-) cells but in the ALDH(high) cells. J Cancer. 2020;11(1):142–52.PubMedPubMedCentralCrossRef
48.
Medina DJ, Goodell L, Glod J, Gelinas C, Rabson AB, Strair RK. Mesenchymal stromal cells protect mantle cell lymphoma cells from spontaneous and drug-induced apoptosis through secretion of B-cell activating factor and activation of the canonical and non-canonical nuclear factor kappaB pathways. Haematologica. 2012;97(8):1255–63.PubMedPubMedCentralCrossRef
49.
Guan J, Huang D, Yakimchuk K, Okret S. p110alpha Inhibition overcomes stromal cell-mediated ibrutinib resistance in mantle cell lymphoma. Mol Cancer Ther. 2018;17(5):1090–100.PubMedCrossRef
50.
Rudelius M, Rosenfeldt MT, Leich E, Rauert-Wunderlich H, Solimando AG, Beilhack A, et al. Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment. Haematologica. 2018;103(1):116–25.PubMedPubMedCentralCrossRef
51.
Balsas P, Palomero J, Eguileor A, Rodriguez ML, Vegliante MC, Planas-Rigol E, et al. SOX11 promotes tumor protective microenvironment interactions through CXCR4 and FAK regulation in mantle cell lymphoma. Blood. 2017;130(4):501–13.PubMedCrossRef
52.
Balsas P, Veloza L, Clot G, Sureda-Gomez M, Rodriguez ML, Masaoutis C, et al. SOX11, CD70, and Treg cells configure the tumor-immune microenvironment of aggressive mantle cell lymphoma. Blood. 2021;138(22):2202–15.PubMedPubMedCentralCrossRef
53.
Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24(30):4867–74.PubMedCrossRef
54.
Davids MS, Roberts AW, Kenkre VP, Wierda WG, Kumar A, Kipps TJ, et al. Long-term follow-up of patients with relapsed or refractory non-hodgkin lymphoma treated with venetoclax in a phase I. First-in-Human Study Clin Cancer Res. 2021;27(17):4690–5.PubMedCrossRef
55.
Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood. 2014;123(22):3398–405.PubMedPubMedCentralCrossRef
56.
Goy A, Sinha R, Williams ME, Kalayoglu Besisik S, Drach J, Ramchandren R, et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study. J Clin Oncol. 2013;31(29):3688–95.PubMedPubMedCentralCrossRef
57.
Trneny M, Lamy T, Walewski J, Belada D, Mayer J, Radford J, et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016;17(3):319–31.PubMedCrossRef
58.
Wang M, Schuster SJ, Phillips T, Lossos IS, Goy A, Rule S, et al. Observational study of lenalidomide in patients with mantle cell lymphoma who relapsed/progressed after or were refractory/intolerant to ibrutinib (MCL-004). J Hematol Oncol. 2017;10(1):171.PubMedPubMedCentralCrossRef
59.
Chong EA, Alanio C, Svoboda J, Nasta SD, Landsburg DJ, Lacey SF, et al. Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy. Blood. 2022;139(7):1026–38.PubMedPubMedCentralCrossRef
60.
Salles G, Gopal AK, Minnema MC, Wakamiya K, Feng H, Schecter JM, et al. Phase 2 study of daratumumab in relapsed/refractory mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19(5):275–84.PubMedCrossRef
61.
Budde LE, Zhang MM, Shustov AR, Pagel JM, Gooley TA, Oliveira GR, et al. A phase I study of pulse high-dose vorinostat (V) plus rituximab (R), ifosphamide, carboplatin, and etoposide (ICE) in patients with relapsed lymphoma. Br J Haematol. 2013;161(2):183–91.PubMedPubMedCentralCrossRef
62.
Evens AM, Balasubramanian S, Vose JM, Harb W, Gordon LI, Langdon R, et al. A phase I/II multicenter, open-label study of the oral histone deacetylase inhibitor abexinostat in relapsed/refractory lymphoma. Clin Cancer Res. 2016;22(5):1059–66.PubMedCrossRef
63.
Leonard JP, LaCasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, et al. Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood. 2012;119(20):4597–607.PubMedCrossRef
64.
Martin P, Ruan J, Furman R, Rutherford S, Allan J, Chen Z, et al. A phase I trial of palbociclib plus bortezomib in previously treated mantle cell lymphoma. Leuk Lymphoma. 2019;60(12):2917–21.PubMedCrossRef
65.
Martin P, Bartlett NL, Blum KA, Park S, Maddocks K, Ruan J, et al. A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma. Blood. 2019;133(11):1201–4.PubMedPubMedCentralCrossRef
66.
Wang M, Popplewell LL, Collins RH Jr, Winter JN, Goy A, Kaminski MS, et al. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study. Br J Haematol. 2014;165(4):510–8.PubMedCrossRef
67.
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, et al. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015;372(10):944–53.PubMedCrossRef
68.
Wang M, Ramchandren R, Chen R, Karlin L, Chong G, Jurczak W, et al. Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study. J Hematol Oncol. 2021;14(1):179.PubMedPubMedCentralCrossRef
69.
Portell CA, Wages NA, Kahl BS, Budde LE, Chen RW, Cohen JB, et al. Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma. Blood Adv. 2022;6(5):1490–8.PubMedPubMedCentral
70.
Wang ML, Lee H, Chuang H, Wagner-Bartak N, Hagemeister F, Westin J, et al. Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: a single-centre, open-label, phase 2 trial. Lancet Oncol. 2016;17(1):48–56.PubMedCrossRef
71.
Morschhauser FA, Cartron G, Thieblemont C, Solal-Celigny P, Haioun C, Bouabdallah R, et al. Obinutuzumab (GA101) monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: results from the phase II GAUGUIN study. J Clin Oncol. 2013;31(23):2912–9.PubMedCrossRef
72.
Le Gouill S, Morschhauser F, Chiron D, Bouabdallah K, Cartron G, Casasnovas O, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 2021;137(7):877–87.PubMedCrossRef
73.
Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, et al. Selinexor combined with ibrutinib demonstrates tolerability and safety in advanced B-cell malignancies: a phase I study. Clin Cancer Res. 2022;28(15):3242–7.PubMedPubMedCentralCrossRef
74.
Goy A, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, et al. Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol. 2009;20(3):520–5.PubMedCrossRef
75.
Lee HJ, Badillo M, Romaguera J, Wang M. A phase II study of carfilzomib in the treatment of relapsed/refractory mantle cell lymphoma. Br J Haematol. 2019;184(3):460–2.PubMedCrossRef
76.
Perez-Galan P, Roue G, Villamor N, Campo E, Colomer D. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak. Blood. 2007;109(10):4441–9.PubMedCrossRef
77.
Yang DT, Young KH, Kahl BS, Markovina S, Miyamoto S. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma. Mol Cancer. 2008;7:40.PubMedPubMedCentralCrossRef
78.
Manni S, Brancalion A, Mandato E, Tubi LQ, Colpo A, Pizzi M, et al. Protein kinase CK2 inhibition down modulates the NF-kappaB and STAT3 survival pathways, enhances the cellular proteotoxic stress and synergistically boosts the cytotoxic effect of bortezomib on multiple myeloma and mantle cell lymphoma cells. PLoS ONE. 2013;8(9):e75280.PubMedPubMedCentralCrossRef
79.
Perez-Galan P, Mora-Jensen H, Weniger MA, Shaffer AL 3rd, Rizzatti EG, Chapman CM, et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood. 2011;117(2):542–52.PubMedPubMedCentralCrossRef
80.
Vegliante MC, Palomero J, Perez-Galan P, Roue G, Castellano G, Navarro A, et al. SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood. 2013;121(12):2175–85.PubMedCrossRef
81.
Desai S, Maurin M, Smith MA, Bolick SC, Dessureault S, Tao J, et al. PRDM1 is required for mantle cell lymphoma response to bortezomib. Mol Cancer Res. 2010;8(6):907–18.PubMedPubMedCentralCrossRef
82.
Bea S, Salaverria I, Armengol L, Pinyol M, Fernandez V, Hartmann EM, et al. Uniparental disomies, homozygous deletions, amplifications, and target genes in mantle cell lymphoma revealed by integrative high-resolution whole-genome profiling. Blood. 2009;113(13):3059–69.PubMedPubMedCentralCrossRef
83.
Zhang Y, Lu P, Zhou Y, Zhang L. Inhibition of LINK-A lncRNA overcomes ibrutinib resistance in mantle cell lymphoma by regulating Akt/Bcl2 pathway. PeerJ. 2021;9:e12571.PubMedPubMedCentralCrossRef
84.
Eyre TA, Walter HS, Iyengar S, Follows G, Cross M, Fox CP, et al. Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Haematologica. 2018.
85.
Zhao S, Kanagal-Shamanna R, Navsaria L, Ok CY, Zhang S, Nomie K, et al. Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients. Am J Hematol. 2020;95(6):623–9.PubMedCrossRef
86.
Sawalha Y, Goyal S, Switchenko JM, Romancik JT, Kamdar M, Greenwell IB, et al. A multicenter analysis of the outcomes with venetoclax in patients with relapsed mantle cell lymphoma. Blood Adv. 2023;7(13):2983–93.PubMedPubMedCentralCrossRef
87.
Zhang L, Nomie K, Zhang H, Bell T, Pham L, Kadri S, et al. B-cell lymphoma patient-derived xenograft models enable drug discovery and are a platform for personalized therapy. Clin Cancer Res. 2017;23(15):4212–23.PubMedPubMedCentralCrossRef
88.
Jain N, Singh S, Laliotis G, Hart A, Muhowski E, Kupcova K, et al. Targeting phosphatidylinositol 3 kinase-beta and -delta for Bruton tyrosine kinase resistance in diffuse large B-cell lymphoma. Blood Adv. 2020;4(18):4382–92.PubMedPubMedCentralCrossRef
89.
Kapoor I, Li Y, Sharma A, Zhu H, Bodo J, Xu W, et al. Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies. Cell Death Dis. 2019;10(12):924.PubMedPubMedCentralCrossRef
90.
Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, et al. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1–1b study. Lancet Haematol. 2019;6(1):e38–47.PubMedCrossRef
91.
Qualls D, Lam HY, Whiting K, Kumar A, Matasar M, Owens C, et al. A phase 1 trial of copanlisib plus ibrutinib in relapsed/refractory mantle cell lymphoma. Blood Adv. 2022;6(18):5262–6.PubMedPubMedCentralCrossRef
92.
Stewart CM, Michaud L, Whiting K, Nakajima R, Nichols C, De Frank S, et al. Phase I/Ib study of the efficacy and safety of buparlisib and ibrutinib therapy in MCL, FL, and DLBCL with serial cell-free DNA monitoring. Clin Cancer Res. 2022;28(1):45–56.PubMedCrossRef
93.
Mehta A, Trněný M, Walewski J, Ribrag V, Dartigeas C, Christensen JH, et al. Efficacy and safety of parsaclisib in patients with relapsed or refractory mantle cell lymphoma not previously treated with a BTK inhibitor: primary analysis from a phase 2 study (CITADEL-205). Blood. 2021;138(Supplement 1):382.CrossRef
94.
Zinzani PL, Delwail V, Paneesha S, Rule S, Martin Garcia-Sancho A, Marin-Niebla A, et al. Phase 2 study evaluating the efficacy and safety of parsaclisib in patients with relapsed or refractory mantle cell lymphoma previously treated with ibrutinib (CITADEL-205). Blood. 2020;136(Supplement 1):43–4.CrossRef
95.
Rudelius M, Pittaluga S, Nishizuka S, Pham TH, Fend F, Jaffe ES, et al. Constitutive activation of Akt contributes to the pathogenesis and survival of mantle cell lymphoma. Blood. 2006;108(5):1668–76.PubMedPubMedCentralCrossRef
96.
Psyrri A, Papageorgiou S, Liakata E, Scorilas A, Rontogianni D, Kontos CK, et al. Phosphatidylinositol 3’-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma. Clin Cancer Res. 2009;15(18):5724–32.PubMedCrossRef
97.
Iyengar S, Clear A, Bodor C, Maharaj L, Lee A, Calaminici M, et al. P110alpha-mediated constitutive PI3K signaling limits the efficacy of p110delta-selective inhibition in mantle cell lymphoma, particularly with multiple relapse. Blood. 2013;121(12):2274–84.PubMedPubMedCentralCrossRef
98.
Al-Mansour M. Treatment landscape of relapsed/refractory mantle cell lymphoma: an updated review. Clin Lymphoma Myeloma Leuk. 2022;22(11):e1019–31.PubMedCrossRef
99.
100.
Desai M, Newberry K, Ou Z, Wang M, Zhang L. Lenalidomide in relapsed or refractory mantle cell lymphoma: overview and perspective. Ther Adv Hematol. 2014;5(3):91–101.PubMedPubMedCentralCrossRef
101.
Zhang L, Yang J, Qian J, Li H, Romaguera JE, Kwak LW, et al. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood. 2012;120(18):3783–92.PubMedPubMedCentralCrossRef
102.
Roue G, Sola B. Management of drug resistance in mantle cell lymphoma. Cancers (Basel). 2020;12(6):1565.PubMedCrossRef
103.
Ameli F, Shajareh E, Mokhtari M, Kosari F. Expression of PD1 and PDL1 as immune-checkpoint inhibitors in mantle cell lymphoma. BMC Cancer. 2022;22(1):848.PubMedPubMedCentralCrossRef
104.
105.
Kim TM, Lakhani N, Gainor J, Kamdar M, Fanning P, Squifflet P, et al. A phase 1 study of ALX148, a CD47 blocker, in combination with rituximab in patients with non-hodgkin lymphoma. Blood. 2019;134(Supplement_1):1953.CrossRef
106.
Freile JA, Ustyanovska Avtenyuk N, Corrales MG, Lourens HJ, Huls G, van Meerten T, et al. CD24 is a potential immunotherapeutic target for mantle cell lymphoma. Biomedicines. 2022;10(5):1175.PubMedPubMedCentralCrossRef
107.
Klapdor R, Wang S, Morgan M, Dork T, Hacker U, Hillemanns P, et al. Characterization of a novel third-generation anti-CD24-CAR against ovarian cancer. Int J Mol Sci. 2019;20(3):660.PubMedPubMedCentralCrossRef
108.
109.
Yang J, Hu G. Significance of PD-L1 in the diagnosis and treatment of B-cell malignant lymphoma. Oncol Lett. 2019;17(3):3382–6.PubMedPubMedCentral
110.
Wang L, Qian J, Lu Y, Li H, Bao H, He D, et al. Immune evasion of mantle cell lymphoma: expression of B7–H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica. 2013;98(9):1458–66.PubMedPubMedCentralCrossRef
111.
Harrington BK, Wheeler E, Hornbuckle K, Shana’ah AY, Youssef Y, Smith L, et al. Modulation of immune checkpoint molecule expression in mantle cell lymphoma. Leuk Lymphoma. 2019;60(10):2498–507.PubMedPubMedCentralCrossRef
112.
Lesokhin AM, Ansell SM, Armand P, Scott EC, Halwani A, Gutierrez M, et al. Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study. J Clin Oncol. 2016;34(23):2698–704.PubMedPubMedCentralCrossRef
113.
Wasiuk A, Testa J, Weidlick J, Sisson C, Vitale L, Widger J, et al. CD27-mediated regulatory T cell depletion and effector T cell costimulation both contribute to antitumor efficacy. J Immunol. 2017;199(12):4110–23.PubMedPubMedCentralCrossRef
114.
Baskar S, Kwong KY, Hofer T, Levy JM, Kennedy MG, Lee E, et al. Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia. Clin Cancer Res. 2008;14(2):396–404.PubMedCrossRef
115.
Karvonen H, Niininen W, Murumagi A, Ungureanu D. Targeting ROR1 identifies new treatment strategies in hematological cancers. Biochem Soc Trans. 2017;45(2):457–64.PubMedCrossRef
116.
Balakrishnan A, Goodpaster T, Randolph-Habecker J, Hoffstrom BG, Jalikis FG, Koch LK, et al. Analysis of ROR1 protein expression in human cancer and normal tissues. Clin Cancer Res. 2017;23(12):3061–71.PubMedCrossRef
117.
Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A, et al. The receptor tyrosine kinase ROR1–an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol. 2014;29:21–31.PubMedCrossRef
118.
Ghaderi A, Zhong W, Okhovat MA, Aschan J, Svensson A, Sander B, et al. A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of mantle cell lymphoma (MCL) cells. Pharmaceutics. 2022;14(10):2238.PubMedPubMedCentralCrossRef
119.
Yu J, Chen Y, Chen L, Zhang L, Rassenti LZ, Widhopf GF 2nd, et al. Cirmtuzumab inhibits ibrutinib-resistant, Wnt5a-induced Rac1 activation and proliferation in mantle cell lymphoma. Oncotarget. 2018;9(37):24731–6.PubMedPubMedCentralCrossRef
120.
Sermer D, Pasqualucci L, Wendel HG, Melnick A, Younes A. Emerging epigenetic-modulating therapies in lymphoma. Nat Rev Clin Oncol. 2019;16(8):494–507.PubMedPubMedCentralCrossRef
121.
Guo H, Zeng D, Zhang H, Bell T, Yao J, Liu Y, et al. Dual inhibition of PI3K signaling and histone deacetylation halts proliferation and induces lethality in mantle cell lymphoma. Oncogene. 2019;38(11):1802–14.PubMedCrossRef
122.
Chaturvedi NK, Hatch ND, Sutton GL, Kling M, Vose JM, Joshi SS. A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib. Leuk Lymphoma. 2019;60(5):1214–23.PubMedCrossRef
123.
Yazbeck V, Shafer D, Perkins EB, Coppola D, Sokol L, Richards KL, et al. A phase II trial of bortezomib and vorinostat in mantle cell lymphoma and diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk 2018;18(9):569–75 e1.
124.
Markozashvili D, Pichugin A, Barat A, Camara-Clayette V, Vasilyeva NV, Lelievre H, et al. Histone deacetylase inhibitor abexinostat affects chromatin organization and gene transcription in normal B cells and in mantle cell lymphoma. Gene. 2016;580(2):134–43.PubMedCrossRef
125.
Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, et al. PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res. 2009;15(10):3354–65.PubMedPubMedCentralCrossRef
126.
Paoluzzi L, Scotto L, Marchi E, Zain J, Seshan VE, O’Connor OA. Romidepsin and belinostat synergize the antineoplastic effect of bortezomib in mantle cell lymphoma. Clin Cancer Res. 2010;16(2):554–65.PubMedCrossRef
127.
Chen Y, Shao X, Zhao X, Ji Y, Liu X, Li P, et al. Targeting protein arginine methyltransferase 5 in cancers: roles, inhibitors and mechanisms. Biomed Pharmacother. 2021;144:112252.PubMedCrossRef
128.
Sloan S, Brown F, Chung JH, Prouty A, Wheeler E, Harrington BK, et al. Targeting PRMT5 to circumvent acquired ibrutinib resistance in mantle cell lymphoma. Blood. 2019;134(Supplement_1):4065.CrossRef
129.
Mareckova A, Malcikova J, Tom N, Pal K, Radova L, Salek D, et al. ATM and TP53 mutations show mutual exclusivity but distinct clinical impact in mantle cell lymphoma patients. Leuk Lymphoma. 2019;60(6):1420–8.PubMedCrossRef
130.
Cheng Q, Chen J. Mechanism of p53 stabilization by ATM after DNA damage. Cell Cycle. 2010;9(3):472–8.PubMedCrossRef
131.
Rosenthal AC, Munoz JL, Villasboas JC. Clinical advances in epigenetic therapies for lymphoma. Clin Epigenet. 2023;15(1):39.CrossRef
132.
Long M, Koirala S, Sloan S, Brown F, Tallada S, Hinterschied C, et al. Acquired resistance to PRMT5 inhibition in mantle cell lymphoma is associated with compensatory activation of multiple signaling pathways. Blood. 2022;140(Supplement 1):3103–4.CrossRef
133.
Queiros AC, Beekman R, Vilarrasa-Blasi R, Duran-Ferrer M, Clot G, Merkel A, et al. Decoding the DNA methylome of mantle cell lymphoma in the light of the entire B cell lineage. Cancer Cell. 2016;30(5):806–21.PubMedPubMedCentralCrossRef
134.
Li XY, Li Y, Zhang L, Liu X, Feng L, Wang X. The antitumor effects of arsenic trioxide in mantle cell lymphoma via targeting Wnt/beta-catenin pathway and DNA methyltransferase-1. Oncol Rep. 2017;38(5):3114–20.PubMedCrossRef
135.
Ribeiro ML, Reyes-Garau D, Armengol M, Fernandez-Serrano M, Roue G. Recent advances in the targeting of epigenetic regulators in B-cell non-hodgkin lymphoma. Front Genet. 2019;10:986.PubMedPubMedCentralCrossRef
136.
137.
Martinez-Baquero D, Sakhdari A, Mo H, Kim DH, Kanagal-Shamanna R, Li S, et al. EZH2 expression is associated with inferior overall survival in mantle cell lymphoma. Mod Pathol. 2021;34(12):2183–91.PubMedPubMedCentralCrossRef
138.
Yang P, Zhang W, Wang J, Liu Y, An R, Jing H. Genomic landscape and prognostic analysis of mantle cell lymphoma. Cancer Gene Ther. 2018;25(5–6):129–40.PubMedCrossRef
139.
Demosthenous C, Gupta SK, Sun J, Wang Y, Troska TP, Gupta M. Deregulation of polycomb repressive complex-2 in mantle cell lymphoma confers growth advantage by epigenetic suppression of cdkn2b. Front Oncol. 2020;10:1226.PubMedPubMedCentralCrossRef
140.
Kagiyama Y, Fujita S, Shima Y, Yamagata K, Katsumoto T, Nakagawa M, et al. CDKN1C-mediated growth inhibition by an EZH1/2 dual inhibitor overcomes resistance of mantle cell lymphoma to ibrutinib. Cancer Sci. 2021;112(6):2314–24.PubMedPubMedCentralCrossRef
141.
Sircar A, Singh S, Xu-Monette ZY, Coyle KM, Hilton LK, Chavdoula E, et al. Exploiting the fibroblast growth factor receptor-1 vulnerability to therapeutically restrict the MYC-EZH2-CDKN1C axis-driven proliferation in Mantle cell lymphoma. Leukemia. 2023. https://​doi.​org/​10.​1038/​s41375-023-02006-8
142.
Sircar A, Singh S, Young KH, Epperla N, Sehgal L. Abstract 1422: Fibroblast growth factor receptor-1 is a novel therapeutic target in mantle cell Lymphoma. Cancer Res. 2023;83(7_Supplement):1422.CrossRef
143.
Keats JA, Lee A, Cunniff JC, Chen W, Mehovic R, Estanek V, et al. Abstract 1161: EZH2 inhibitor tazemetostat demonstrates activity in preclinical models of Bruton’s tyrosine kinase inhibitor-resistant relapsed/refractory mantle cell lymphoma. Can Res. 2021;81(131):1161.CrossRef
144.
145.
Okada T, Ngo VN, Ekland EH, Forster R, Lipp M, Littman DR, et al. Chemokine requirements for B cell entry to lymph nodes and Peyer’s patches. J Exp Med. 2002;196(1):65–75.PubMedPubMedCentralCrossRef
146.
Kurtova AV, Tamayo AT, Ford RJ, Burger JA. Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood. 2009;113(19):4604–13.PubMedPubMedCentralCrossRef
147.
Chen Z, Teo AE, McCarty N. ROS-induced CXCR4 signaling regulates mantle cell lymphoma (MCL) cell survival and drug resistance in the bone marrow microenvironment via autophagy. Clin Cancer Res. 2016;22(1):187–99.PubMedCrossRef
148.
Kwon D, Takata K, Zhang Z, Chong L, Fraser B, Zeisler J, et al. Targeting refractory mantle cell lymphoma for imaging and therapy using C-X-C chemokine receptor type 4 radioligands. Clin Cancer Res. 2022;28(8):1628–39.PubMedPubMedCentralCrossRef
149.
Micallef IN, Stiff PJ, Nademanee AP, Maziarz RT, Horwitz ME, Stadtmauer EA, et al. Plerixafor plus granulocyte colony-stimulating factor for patients with non-Hodgkin lymphoma and multiple myeloma: long-term follow-up report. Biol Blood Marrow Transplant. 2018;24(6):1187–95.PubMedPubMedCentralCrossRef
150.
Kersy O, Salmon-Divon M, Gomes da Silva M, Moita AF, Cabecadas J, Klener P Jr, et al. Inhibition of MAPK-ERK signaling pathway overcomes microrna-mediated ibrutinib resistance in mantle cell lymphoma. Blood. 2022;140(Supplement 1):3109–10.CrossRef
151.
Wang X, Fei Y, Liu X, Zhang T, Li W, Jia X, et al. Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. Aging (Albany NY). 2021;13(17):21102–21.PubMedCrossRef
152.
Morrison VA, Jung SH, Johnson J, LaCasce A, Blum KA, Bartlett NL, et al. Therapy with bortezomib plus lenalidomide for relapsed/refractory mantle cell lymphoma: final results of a phase II trial (CALGB 50501). Leuk Lymphoma. 2015;56(4):958–64.PubMedCrossRef
153.
Srour SA, Lee HJ, Nomie K, Ye H, Chen W, Oriabure O, et al. Novel chemotherapy-free combination regimen for ibrutinib-resistant mantle cell lymphoma. Br J Haematol. 2018;181(4):561–4.PubMedCrossRef
154.
Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, et al. Ibrutinib plus venetoclax for the treatment of mantle-cell lymphoma. N Engl J Med. 2018;378(13):1211–23.PubMedCrossRef
155.
Li Y, Bouchlaka MN, Wolff J, Grindle KM, Lu L, Qian S, et al. FBXO10 deficiency and BTK activation upregulate BCL2 expression in mantle cell lymphoma. Oncogene. 2016;35(48):6223–34.PubMedPubMedCentralCrossRef
156.
Zhao X, Bodo J, Sun D, Durkin L, Lin J, Smith MR, et al. Combination of ibrutinib with ABT-199: synergistic effects on proliferation inhibition and apoptosis in mantle cell lymphoma cells through perturbation of BTK, AKT and BCL2 pathways. Br J Haematol. 2015;168(5):765–8.PubMedCrossRef
157.
Zhang H, Local A, Benbatoul K, Folger P, Sheng S, Tsai C-Y, et al. CG ’806, a first-in-class non-covalent pan-FLT3/BTK inhibitor, exerts superior potency against B-cell malignant cells. Blood. 2017;130(11):5200.
158.
Thieme E, Liu T, Bruss N, Roleder C, Lam V, Wang X, et al. Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma. Cell Death Dis. 2022;13(3):246.PubMedPubMedCentralCrossRef
159.
Tsukamoto T, Nakahata S, Sato R, Kanai A, Nakano M, Chinen Y, et al. BRD4-regulated molecular targets in mantle cell lymphoma: insights into targeted therapeutic approach. Cancer Genomics Proteomics. 2020;17(1):77–89.PubMedPubMedCentralCrossRef
160.
Sun B, Shah B, Fiskus W, Qi J, Rajapakshe K, Coarfa C, et al. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015;126(13):1565–74.PubMedPubMedCentralCrossRef
161.
Soumerai JD, Diefenbach CS, Samaniego F, Kumar A, Tsai ML, Asch AS, et al. Safety and efficacy of the PI3Kδ inhibitor zandelisib in combination with the BTK inhibitor zanubrutinib in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or mantle cell lymphoma (MCL). Blood. 2022;140(Supplement 1):189–91.CrossRef
162.
Jerkeman M, Kolstad A, Hutchings M, Pasanen A, Meriranta L, Niemann CU, et al. Venetoclax, lenalidomide and rituximab for patients with relapsed or refractory mantle cell lymphoma—the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II trial. Blood. 2022;140(Supplement 1):184–5.CrossRef
163.
Alinari L, Yu B, Christian BA, Yan F, Shin J, Lapalombella R, et al. Combination anti-CD74 (milatuzumab) and anti-CD20 (rituximab) monoclonal antibody therapy has in vitro and in vivo activity in mantle cell lymphoma. Blood. 2011;117(17):4530–41.PubMedPubMedCentralCrossRef
164.
Chiron D, Bellanger C, Papin A, Tessoulin B, Dousset C, Maiga S, et al. Rational targeted therapies to overcome microenvironment-dependent expansion of mantle cell lymphoma. Blood. 2016;128(24):2808–18.PubMedCrossRef
165.
Zhou X, Steinhardt MJ, Dull J, Krummenast F, Danhof S, Meckel K, et al. Obinutuzumab and venetoclax induced complete remission in a patient with ibrutinib-resistant non-nodal leukemic mantle cell lymphoma. Eur J Haematol. 2020;104(4):352–5.PubMedCrossRef
166.
Decombis S, Bellanger C, Le Bris Y, Boulet D, Jardine J, Dousset C, et al. CARD11 and BCL2A1 join forces to promote resistance to ibrutinib/venetoclax combination in lymphoma patients. Blood. 2022;140(Supplement 1):2044–5.CrossRef
167.
Sawas A, Farber CM, Schreeder MT, Khalil MY, Mahadevan D, Deng C, et al. A phase 1/2 trial of ublituximab, a novel anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab. Br J Haematol. 2017;177(2):243–53.PubMedPubMedCentralCrossRef
168.
Deshpande A, Wang Y, Munoz J, Jain P. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. Drugs Today (Barc). 2022;58(6):283–98.PubMedCrossRef
169.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020;382(14):1331–42.PubMedPubMedCentralCrossRef
170.
Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023;41(3):555–67.PubMedCrossRef
171.
Herbaux C, Bret C, Di Blasi R, Bachy E, Beauvais D, Gat E, et al. Kte-X19 in relapsed or refractory mantle-cell lymphoma, a “real-life” study from the descar-T registry and lysa group. Blood. 2021;138(Supplement 1):743.CrossRef
172.
Wang Y, Jain P, Locke FL, Munoz J, Maurer MJ, Beitinjaneh A, et al. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real world experience from the US lymphoma CAR T consortium. Blood. 2021;138(Supplement 1):744.CrossRef
173.
O’Reilly MA, Sanderson R, Wilson W, Burns D, Besley C, Creasey T, et al. Brexucabtagene autoleucel for relapsed/refractory mantle cell lymphoma: real-world outcomes in the United Kingdom. Blood. 2022;140(Supplement 1):7519–21.CrossRef
174.
Palomba ML, Gordon LI, Siddiqi T, Abramson JS, Kamdar M, Lunning MA, et al. Safety and preliminary efficacy in patients with relapsed/refractory mantle cell lymphoma receiving lisocabtagene maraleucel in transcend NHL 001. Blood. 2020;136(Supplement 1):10–1.CrossRef
175.
Ying Z, Zhou K, Li L, Li W, Yang S, Liu Y, et al. Preliminary safety and efficacy of relmacabtagene autoleucel (relma-cel) in adults with relapsed/refractory mantle cell lymphoma (r/r MCL) in China. Blood. 2022;140(Supplement 1):7470–1.CrossRef
176.
Qin H, Dong Z, Wang X, Cheng WA, Wen F, Xue W, et al. CAR T cells targeting BAFF-R can overcome CD19 antigen loss in B cell malignancies. Sci Transl Med. 2019;11(511):eaaw414.CrossRef
177.
George P, Dasyam N, Giunti G, Mester B, Bauer E, Andrews B, et al. Third-generation anti-CD19 chimeric antigen receptor T-cells incorporating a TLR2 domain for relapsed or refractory B-cell lymphoma: a phase I clinical trial protocol (ENABLE). BMJ Open. 2020;10(2):e034629.PubMedPubMedCentralCrossRef
178.
Chan T, Scott SP, Du M, Bolinger C, Poortman C, Shepard L, et al. Preclinical evaluation of Prgn-3007, a non-viral, multigenic, autologous ROR1 Ultracar-T ® therapy with novel mechanism of intrinsic pd-1 blockade for treatment of hematological and solid cancers. Blood. 2021;138(Supplement 1):1694.CrossRef
179.
Scarfo I, Ormhoj M, Frigault MJ, Castano AP, Lorrey S, Bouffard AA, et al. Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas. Blood. 2018;132(14):1495–506.PubMedPubMedCentralCrossRef
180.
Minson A, Hamad N, Butler JP, Westerman DA, Ritchie D, Blombery P, et al. A Phase II, open-label, single arm trial to assess the efficacy and safety of the combination of tisagenlecleucel and ibrutinib in mantle cell lymphoma (TARMAC). Blood. 2020;136(Supplement 1):34–5.CrossRef
181.
Shah NN, Johnson BD, Schneider D, Zhu F, Szabo A, Keever-Taylor CA, et al. Bispecific anti-CD20, anti-CD19 CAR T cells for relapsed B cell malignancies: a phase 1 dose escalation and expansion trial. Nat Med. 2020;26(10):1569–75.PubMedCrossRef
182.
183.
Fraietta JA, Beckwith KA, Patel PR, Ruella M, Zheng Z, Barrett DM, et al. Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood. 2016;127(9):1117–27.PubMedPubMedCentralCrossRef
184.
Qin JS, Johnstone TG, Baturevych A, Hause RJ, Ragan SP, Clouser CR, et al. Antitumor potency of an anti-CD19 chimeric antigen receptor T-cell therapy, lisocabtagene maraleucel in combination with ibrutinib or acalabrutinib. J Immunother. 2020;43(4):107–20.PubMedPubMedCentralCrossRef
185.
Ruella M, Kenderian SS, Shestova O, Fraietta JA, Qayyum S, Zhang Q, et al. The addition of the BTK inhibitor ibrutinib to anti-CD19 chimeric antigen receptor T cells (CART19) improves responses against mantle cell lymphoma. Clin Cancer Res. 2016;22(11):2684–96.PubMedCrossRef
186.
Minson A, Hamad N, Cheah CY, Tam CS, Blombery P, Westerman DA, et al. Time-limited ibrutinib and tisagenlecleucel is highly effective in the treatment of patients with relapsed or refractory mantle cell lymphoma, including those with TP53 mutated and btki-refractory disease: first report of the tarmac study. Blood. 2022;140(Supplement 1):181–3.CrossRef
187.
Jiang VC, Yan F, Jordan AA, Che Y, Liu Y, Cai Q, et al. Targeting the HSP90-MYC-CDK9 axis to overcome dual resistance to BTK inhibition and CAR-T therapy in mantle cell lymphoma. Blood. 2022;140(Supplement 1):3512–3.CrossRef
188.
Zhou J, Kulkarni A, Love C, Happ L, Sturtevant D, Biyani N, et al. Development of a potent DNA damaging agent LP-284 for treatment of mantle cell lymphoma. Blood. 2022;140(Supplement 1):4940–1.CrossRef
189.
Yang M, Wang L, Ni M, Neuber B, Wang S, Gong W, et al. Pre-sensitization of malignant B cells through venetoclax significantly improves the cytotoxic efficacy of CD19.CAR-T cells. Front Immunol. 2020;11:608167.PubMedPubMedCentralCrossRef
190.
Bukhari A, El Chaer F, Koka R, Singh Z, Hutnick E, Ruehle K, et al. Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss. Am J Hematol. 2019;94(10):E273–5.PubMedCrossRef
191.
Shah NN, Furqan F, Szabo A, Neumann J, Hari P, Schneider D, et al. Results from a phase 1/2 study of tandem, bispecific anti-CD20/Anti-CD19 (LV20.19) CAR T-cells for mantle cell lymphoma. Blood. 2022;140(11):9318–9.CrossRef
192.
Goebeler ME, Knop S, Viardot A, Kufer P, Topp MS, Einsele H, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;34(10):1104–11.PubMedCrossRef
193.
Hutchings M, Mous R, Clausen MR, Johnson P, Linton KM, Chamuleau MED, et al. Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study. Lancet. 2021;398(10306):1157–69.PubMedCrossRef
194.
Bannerji R, Arnason JE, Advani RH, Brown JR, Allan JN, Ansell SM, et al. Odronextamab, a human CD20xCD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial. Lancet Haematol. 2022;9(5):e327–39.PubMedCrossRef
195.
Topp MS, Gokbuget N, Zugmaier G, Stein AS, Dombret H, Chen Y, et al. Long-term survival of patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab. Cancer. 2021;127(4):554–9.PubMedCrossRef
196.
Budde LE, Assouline S, Sehn LH, Schuster SJ, Yoon SS, Yoon DH, et al. Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study. J Clin Oncol. 2022;40(5):481–91.PubMedCrossRef
197.
Phillips TJ, Dickinson M, Morschhauser F, Bachy E, Crump M, Trněný M, et al. Glofitamab monotherapy induces high complete response rates in patients with heavily pretreated relapsed or refractory mantle cell lymphoma. Blood. 2022;140(Supplement 1):178–80.CrossRef
198.
Wang ML, Barrientos JC, Furman RR, Mei M, Barr PM, Choi MY, et al. Zilovertamab Vedotin targeting of ROR1 as therapy for lymphoid cancers. NEJM Evidence. 2022;1(1):EVIDoa2100001.
199.
Lee HJ, Choi MY, Siddiqi T, Rhodes JM, Wierda WG, Isufi I, et al. Phase 1/2 study of zilovertamab and ibrutinib in mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), or marginal zone lymphoma (MZL). Blood. 2022;140(Supplement 1):566–8.CrossRef
200.
201.
Jiang VC, Liu Y, Jordan A, McIntosh J, Li Y, Che Y, et al. The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma. J Hematol Oncol. 2021;14(1):132.PubMedPubMedCentralCrossRef
202.
Hamadani M, Radford J, Carlo-Stella C, Caimi PF, Reid E, O’Connor OA, et al. Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021;137(19):2634–45.PubMedPubMedCentralCrossRef
203.
Sawas A, Savage KJ, Perez R, Advani RH, Butturini A, Lackey J, et al. A phase 1 study of the Anti-CD37 antibody-drug conjugate AGS67E in advanced lymphoid malignancies. Interim results. Blood. 2015;126(23):3976.CrossRef
204.
Sangha R, Davies A, Dang NH, Ogura M, MacDonald DA, Ananthakrishnan R, et al. Phase 1 study of inotuzumab ozogamicin combined with R-GDP for the treatment of patients with relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma. J Drug Assess. 2017;6(1):10–7.PubMedPubMedCentralCrossRef
205.
Phillips T, Barr PM, Park SI, Kolibaba K, Caimi PF, Chhabra S, et al. A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphoma. Invest New Drugs. 2019;37(2):297–306.PubMedCrossRef
Metadata
Title
Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
Authors
Neeraj Jain
Mukesh Mamgain
Sayan Mullick Chowdhury
Udita Jindal
Isha Sharma
Lalit Sehgal
Narendranath Epperla
Publication date
01-12-2023
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2023
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-023-01496-4

Other articles of this Issue 1/2023

Journal of Hematology & Oncology 1/2023 Go to the issue

Correspondence

Immunotherapies targeting GPRC5D in relapsed or refractory multiple myeloma: latest updates from 2022 ASH Annual Meeting

Correspondence

The development of a cSMART-based integrated model for hepatocellular carcinoma diagnosis

Review

Development and application of nanomaterials, nanotechnology and nanomedicine for treating hematological malignancies

Review

The functional and clinical roles of liquid biopsy in patient-derived models

Research

Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression

Correction

Correction: Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits